primary intraocular lymphoma
Conditions
Interventions
ZR-MTX:Rituximab,zanubrutinib, methotrexate
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Patients with treatment-naïve primary intraocular lymphoma who are pathologically confirmed or meet the criteria for the diagnosis of intraocular lymphoma; 2.Age 18-75 years old; 3.Physical Fitness Score (ECOG) = 1.0×10^9/L, PLT>50×10^9/L); 6.Creatinine clearance = 30 ml/min (calculated by Cockcroft-Gault formula); 7.Liver function tests: total bilirubin = 2.0 times the upper limit of normal, ALT <= 3 times the upper normal limit; 8.Patients of childbearing potential must guarantee strict, highly effective contraception for the duration of the study.
Exclusion criteria
Exclusion criteria: 1.Patients with primary intraocular lymphoma involving the intracranial region; 2.Patients with ocular involvement of systemic lymphoma; 3.Uncontrolled active infections; 4.Organic heart disease accompanied by obvious clinical symptoms, such as uncontrolled arrhythmia, uncontrolled heart failure, uncontrolled hypertension, etc., can be classified according to the New York Heart Association (NYHA) grading system; 5.Strong CYP3A inducers or inhibitors should be taken simultaneously; 6.Need to use anticoagulant drugs simultaneously; 7.Known to have human immunodeficiency virus (HIV) infection, or serological tests showing active hepatitis B or C virus infection (HBsAg positive or HCV-RNA positive); 8.Subjects who are known or suspected to be unable to comply with the research protocol Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall reponse rate and complete remission rate during induction therapy;Overall survival;Safery; | — |
Countries
China
Contacts
Public ContactWei Zhang
Peking Union Medical College Hospital
Outcome results
None listed